Search Results for "CT P6 Celltrion"
Celltrion Inc. (biosimilars of blockbuster biologics), its Celltrion Healthcare division, and Hospira Inc. (specialty generic injectables) will collaborate on the manufacturing and supply of eight bio...
Celltrion, a Korean biotech, filed with the FDA for approval of Remsima®, a biosimilar to Janssen’s Remicade, which is indicated for autoimmune diseases. Remsima is the first monoclonal anti...
Celltrion, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Celltrion, Inc. - Product Pipeline Review - 2014’, provides an overview of the Celltrion, Inc.’s pharmaceutic...
SEOUL, July 2 (Reuters) - Celltrion Inc said on Wednesday its top shareholder is no longer considering a sale of a stake in the biotechnology company.
Following a Japanese approval last week Celltrion and partner Nippon Kayaku have claimed the US as the next target market for their Remicade (infliximab) biosimilar.
Celltrion Inc. (KOSDAQ:068270) submitted an application to FDA for Remsima infliximab, a biosimilar of Remicade from Johnson & Johnson (NYSE:JNJ) and
South Korean biotechnology company Celltrion filed a lawsuit on 31 March 2014 in a federal court in Massachusetts seeking a declaratory judgement that Janssen Biotech’s (Janssen) remaining patents o...
South Korea’s Celltrion and Japanese partner Nippon Kayaku eye the U.S. for the next approval of their biosimilar of Johnson & Johnson’s Remicade.
Matching PubMed Articles